ACADIA PHARMACEUTICALS INC's ticker is ACAD and the CUSIP is 004225108. A total of 279 filers reported holding ACADIA PHARMACEUTICALS INC in Q4 2019. The put-call ratio across all filers is 0.89 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2021 | $2,988,000 | -61.4% | 115,820 | -20.0% | 0.29% | -62.8% |
| Q4 2020 | $7,737,000 | +27.9% | 144,720 | -1.3% | 0.78% | +15.7% |
| Q3 2020 | $6,048,000 | -13.6% | 146,620 | +1.6% | 0.68% | -21.1% |
| Q2 2020 | $6,998,000 | +12.2% | 144,370 | -2.2% | 0.86% | -6.9% |
| Q1 2020 | $6,235,000 | -1.2% | 147,570 | +0.1% | 0.92% | +25.1% |
| Q4 2019 | $6,309,000 | +1.1% | 147,470 | -0.1% | 0.74% | -7.7% |
| Q3 2019 | $6,239,000 | +49.4% | 147,640 | -5.5% | 0.80% | +47.6% |
| Q2 2019 | $4,177,000 | -2.4% | 156,280 | -1.9% | 0.54% | -4.3% |
| Q1 2019 | $4,278,000 | +24.6% | 159,330 | +2.6% | 0.56% | +17.0% |
| Q4 2018 | $3,433,000 | -10.0% | 155,330 | -15.5% | 0.48% | +2.3% |
| Q3 2018 | $3,816,000 | +35.5% | 183,830 | -0.4% | 0.47% | +26.3% |
| Q2 2018 | $2,817,000 | -40.4% | 184,510 | -12.3% | 0.37% | -37.1% |
| Q1 2018 | $4,727,000 | -21.7% | 210,390 | +5.0% | 0.59% | -18.9% |
| Q4 2017 | $6,036,000 | – | 200,460 | – | 0.73% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Fairmount Funds Management LLC | 647,833 | $26,723,000 | 11.32% |
| GREAT POINT PARTNERS LLC | 1,921,563 | $79,264,000 | 7.13% |
| Baker Brothers Advisors | 41,904,586 | $1,728,564,000 | 6.91% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 486,000 | $20,048,000 | 6.47% |
| Palo Alto Investors LP | 1,832,300 | $75,582,000 | 4.15% |
| Birchview Capital, LP | 204,000 | $8,416,000 | 2.81% |
| SECTORAL ASSET MANAGEMENT INC | 556,514 | $22,956,000 | 1.97% |
| Rock Springs Capital Management LP | 1,573,200 | $64,895,000 | 1.65% |
| Riggs Asset Managment Co. Inc. | 17,470 | $2,025,000 | 0.85% |
| PFM Health Sciences, LP | 421,087 | $17,370,000 | 0.80% |